Why the study?
Despite MAPSE being fast, simple, and less reliant on image quality, no major imaging guidelines advise its routine measurement.
Does MAPSE measurement improve the detection of systolic dysfunction and prognostication compared to LVEF and GLS in adult cardiology patients?
Does MAPSE measurement improve the detection of systolic dysfunction and prognostication compared to LVEF and GLS in adult cardiology patients?
MAPSE is an easily attainable imaging biomarker that correlates well with LVEF and GLS, detects early systolic dysfunction, and offers strong prognostic value, suggesting it should be integrated into routine cardiac imaging.
MAPSE may enable earlier systolic dysfunction detection on routine echo; leaves open its added prognostic value over LVEF or GLS.
Movement of the mitral annulus towards the left ventricular (LV) apex during systole, termed atrioventricular plane displacement (AVPD) or mitral annular plane systolic excursion (MAPSE), was first observed by Leonardo da Vinci in the 15 th century. MAPSE, a measure of longitudinal movement, shows good agreement between transthoracic echocardiography and cardiac magnetic resonance imaging (CMR), and can also be measured by transesophageal echocardiography and gated cardiac computed tomography. Manual measurement is fast, simple, and less reliant on good echocardiographic image quality than left ventricular ejection fraction (LVEF) or global longitudinal strain (GLS). Also, measurement can be easily automated, reducing reporting time. However, no major imaging guidelines advise routine measurement. We present a systematic review of studies appraising the diagnostic and prognostic performance of MAPSE from PubMed, Medline, Google Scholar and Embase until September 2025 in accordance with the PRISMA statement. Our findings demonstrate that MAPSE correlates with both LVEF ( r =0.64 [95% confidence interval 0.54– 0.74]) and GLS ( r =0.53 [0.45–0.63]), thus showing a modest association with measures of systolic function that may be particularly useful in patients with poor echocardiographic windows. Importantly, MAPSE falls while LVEF remains preserved across a range of pathologies, enabling earlier detection of systolic impairment than when using LVEF. MAPSE is also a powerful prognostic tool, outperforming both LVEF and GLS in predicting adverse events in several studies. Taken together, MAPSE has a clinically useful and important role that merits integration into routine cardiac imaging and care.
No takes yet. Share an insight, caveat, or question.
Falconer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: